Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients With BRAFV600-mutated Metastatic Melanoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0720
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Thrombophilic Status May Predict Prognosis in Patients With Metastatic BRAFV600-mutated Melanoma Who Are Receiving BRAF Inhibitors

Journal of the American Academy of Dermatology
Dermatology
2016English

Vemurafenib Has Activity in Patients With BRAFV600-Mutant Glioma

Cancer Discovery
Oncology
2018English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

Metastatic Melanoma and Vemurafenib: Novel Approaches

Rare Tumors
OncologyHistology
2012English

Biomarker Analysis of On-Treatment and at Progression Biopsies From BRIM7 - A Phase 1B Trial of Combined Vemurafenib and Cobimetinib Treatment in BRAF V600 Mutated Melanoma

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Simultaneous Treatment of Severe Vemurafenib-Induced Uveitis and Metastatic Melanoma

Journal of Clinical & Experimental Ophthalmology
2016English

Prognostic Factors Related to Clinical Response in Patients With Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Clinical Cancer Research
Cancer ResearchOncology
2007English

Successful Dabrafenib Transition After Vemurafenib-Induced Toxic Epidermal Necrolysis in a Patient With Metastatic Melanoma

JAAD Case Reports
Dermatology
2018English

Risk Factors for Severe Rash With Use of Vemurafenib Alone or in Combination With Cobimetinib for Advanced Melanoma: Pooled Analysis of Clinical Trials

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy